RxDoctor Payments Data

Giselle Lynch, MD

Ophthalmology · Paramus, NJNPI 1114488111

Payments from drug & device makers

$698in general payments, 2019–2025

Across 18 payments — averaging $38.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$159
  • Alcon$149
  • Sight Sciences, Inc.$103
  • AbbVie$67
  • Bausch & Lomb Americas Inc.$61
  • Sun Pharmaceutical Industries Inc.$48
  • plus $112 from 3 others

What the payments were for

  • Food & beverage$698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$698 in reported general payments places this provider in the 30th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$30,975
Medicare patients
152
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate80$32,648
Brimonidine Tartrate270$20,171
RocklatanNetarsudil Mesylat/Latanoprost47$17,368
CombiganBrimonidine Tartrate/Timolol31$10,098
LumiganBimatoprost27$9,974
RestasisCyclosporine13$8,103
Brinzolamide24$4,324
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat266$4,009
Latanoprost438$3,927
Alphagan PBrimonidine Tartrate13$3,885
Travoprost30$3,567
Methazolamide19$3,411
SimbrinzaBrinzolamide/Brimonidine Tart15$3,359
TafluprostTafluprost/Pf13$3,310
Prednisolone Acetate78$3,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan, Restasis, Alphagan P$67$32,06084 claims
AlconSimbrinza$149$3,35915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →